Companies: 10,795·Total market cap: $144.5T
XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd.

XTLBNASDAQHealthcare● Active
$2.07
+$0.01(+0.49%)
Market Cap$4896806
P/E Ratio—
52W High$10.28
52W Low$2
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

XTL Biopharmaceuticals Ltd. (XTLB) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001023549 · XTLB · NASDAQ · as of Jun 8, 2026

Filing snapshot

539
Total Filings
6-K
Latest Form
2026-05-22
Most Recent
2005
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001023549 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-04-30
Fiscal Year End
Apr 30, 2025
Accession No.
0001213900-25-037590
Primary Document
ea0239661-20f_xtlbio.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001023549 · Accession 0001213900-25-037590

Latest Key Filings

6-KQuarterly Report
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-22
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-22
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-07
View
NT 20-FNT 20-F
NOTIFICATION OF LATE FILING
2026-04-30
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-04-29
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-23
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-23
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-03-20
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-03-10
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-02-27
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-02-24
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-02-23
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-02-17
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-01-28
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-01-23
View
Showing 1–15 of 502 filingsForm 4 / 144 hidden· 539 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001023549  |  Exchange: NASDAQ · Healthcare

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) has submitted 539 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2005. As a Healthcare sector company with CIK 0001023549, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is XTL Biopharmaceuticals Ltd.'s most comprehensive regulatory disclosure. The most recent XTL Biopharmaceuticals Ltd. 10-K was filed on 2025-04-30 for fiscal year ending 2025. Historical XTLB 10-K annual reports are available from 2004 through 2025.

Investors researching XTL Biopharmaceuticals Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
KALA SEC Filings →PLRZ SEC Filings →CYCN SEC Filings →VYNE SEC Filings →RADX SEC Filings →TCRT SEC Filings →KTTA SEC Filings →QNRX SEC Filings →
→ XTLB Financials→ XTLB Earnings→ XTLB Insider Trades

Frequently Asked Questions

XTLB SEC Filings · 8 questions

XTL Biopharmaceuticals Ltd. (XTLB) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 539 filings and access original documents at no cost. XTL Biopharmaceuticals Ltd.'s CIK is 0001023549.

XTLB SEC filingsXTL Biopharmaceuticals Ltd. SEC documentsfind XTLB 10-K